Oquendo Gabriel Velez, Kilaru Vikas, Balaji Nivedha, Dakkak Tahani, Olukayode Oluwafemi, Acosta Giancarlo
Department of Internal Medicine, Northeast Georgia Medical Center, Gainesville, GA, USA.
GME Research Department, Northeast Georgia Medical Center, Gainesville, GA, USA.
J Racial Ethn Health Disparities. 2025 Sep 16. doi: 10.1007/s40615-025-02657-6.
To assess ethnic disparities in 90-day outcomes among patients hospitalized with acute decompensated heart failure (ADHF), and in the use of guideline-directed medical therapy (GDMT) among those with heart failure with reduced ejection fraction (HFrEF).
This retrospective cohort study included patients hospitalized with ADHF at a medium-sized health system between January 2018 and May 2024. Primary outcomes were 90-day mortality and readmission. Among patients with HFrEF, GDMT use was assessed as a secondary outcome. Multilevel logistic regression was used to evaluate associations between ethnicity and outcomes.
A total of 14,644 patients with ADHF were included. No significant differences were observed in 90-day mortality (OR 0.69, 95% CI 0.21-2.24, P = 0.540) or 90-day readmission (OR 0.78, 95% CI 0.51-1.19, P = 0.267) between Hispanic and non-Hispanic patients. Among HFrEF patients, Hispanic patients had higher odds of receiving beta blockers (OR 1.32, 95% CI 1.04-1.68, p = 0.023), mineralocorticoid receptor antagonists (OR 1.37, 95% CI 1.05-1.79, p = 0.021), and renin-angiotensin system blockers (OR 1.51, 95% CI 1.17-1.95, p = 0.002). In contrast, no significant difference was observed in the use of sodium-glucose cotransporter-2 inhibitors between the two groups (OR 1.67, 95% CI 0.69-4.05, p = 0.254). Additionally, patients with Medicare (OR 0.65, 95% CI 0.57-0.74, p < 0.001) or unspecified insurance (OR 0.18, 95% CI 0.11-0.28, p < 0.001) had lower odds of receiving GDMT compared to self-pay patients.
This study reveals a counterintuitive pattern of higher GDMT use among Hispanic HFrEF patients, underscoring the need to leverage community-based resources and patient assistance programs to address disparities. Further prospective studies are needed to confirm these findings or policy changes to reduce insurance-related barriers to GDMT.
评估急性失代偿性心力衰竭(ADHF)住院患者90天预后的种族差异,以及射血分数降低的心力衰竭(HFrEF)患者中使用指南指导的药物治疗(GDMT)的情况。
这项回顾性队列研究纳入了2018年1月至2024年5月期间在一个中等规模医疗系统中因ADHF住院的患者。主要结局是90天死亡率和再入院率。在HFrEF患者中,评估GDMT的使用情况作为次要结局。采用多水平逻辑回归来评估种族与结局之间的关联。
共纳入14644例ADHF患者。西班牙裔和非西班牙裔患者在90天死亡率(比值比[OR]0.69,95%置信区间[CI]0.21 - 2.24,P = 0.540)或90天再入院率(OR 0.78,95% CI 0.51 - 1.19,P = 0.267)方面未观察到显著差异。在HFrEF患者中,西班牙裔患者接受β受体阻滞剂(OR 1.32,95% CI 1.04 - 1.68,p = 0.023)、盐皮质激素受体拮抗剂(OR 1.37,95% CI 1.05 - 1.79,p = 0.021)和肾素 - 血管紧张素系统阻滞剂(OR 1.51,95% CI 1.17 - 1.95,p = 0.002)的几率更高。相比之下,两组在使用钠 - 葡萄糖协同转运蛋白2抑制剂方面未观察到显著差异(OR 1.67,95% CI 0.69 - 4.05,p = 0.254)。此外,与自费患者相比,拥有医疗保险(OR 0.65,95% CI 0.57 - 0.74,p < 0.001)或未明确保险类型(OR 0.18,95% CI 0.11 - 0.28,p < 0.001)的患者接受GDMT的几率较低。
本研究揭示了西班牙裔HFrEF患者中GDMT使用较高这一与直觉相悖的模式,强调需要利用基于社区的资源和患者援助计划来解决差异问题。需要进一步的前瞻性研究来证实这些发现或进行政策改变,以减少与保险相关的GDMT使用障碍。